AI in Healthcare
The latest on artificial intelligence transforming medicine
News stories discovered and organized by an automated pipeline. Covering clinical deployments, research breakthroughs, regulation, and industry developments.
Parkinson’s Imaging AI Wins De Novo Clearance, Opening a New Diagnostic Category
An AI-based MRI diagnostic aid for parkinsonian syndromes has received FDA De Novo classification, creating a first-in-class regulatory category. The clearance is notable both clinically and strategically, as neuroimaging AI has struggled to move from promising research into routine diagnostic use.
FDA Grants De Novo Clearance to First-in-Class AI MRI Aid for Parkinsonian Syndromes
Neuropacs has won De Novo classification from the FDA for an AI-based MRI diagnostic aid designed to help identify Parkinsonian syndromes. The clearance gives the product a new regulatory category and signals that imaging AI is moving deeper into neurology.
Real-Time EEG Interpretation AI Could Change ICU Neurology Workflows
Cleveland Clinic is spotlighting AI designed to provide real-time EEG interpretation in the ICU, where specialist availability and time-sensitive decisions can delay care. If validated in practice, the approach could make continuous neurologic monitoring more actionable for critical care teams.
FDA Clears Zeto’s Outpatient EEG System, Pointing to a More Portable Neurology Future
Zeto has secured FDA clearance for its New Wave outpatient EEG system, adding to a growing category of portable neurology tools. The clearance reflects rising demand for diagnostics that can move outside traditional hospital settings without sacrificing data quality.
FDA Clears Zeto’s Outpatient EEG System, Expanding AI-Enabled Neurology Monitoring
Zeto has secured FDA clearance for its New Wave outpatient EEG system, a sign that AI-assisted neurological monitoring is spreading beyond hospitals and into ambulatory care. The clearance could help ease access bottlenecks for epilepsy and other EEG-dependent evaluations.
GLP-1 Drugs Are Expanding Beyond Obesity, and Neurology May Be the Next Real Test
Two reports this week spotlight the widening clinical conversation around GLP-1 medicines, including their potential role beyond weight loss and promising signals in chronic migraine. Together they show how one of medicine’s hottest drug classes is evolving into a broader platform story that could reshape care pathways well outside endocrinology.
AI for ALS research reflects a broader shift toward using models where biology is hardest
NBC Bay Area reports on how the medical community is using AI to pursue new paths in ALS, a disease area marked by biological complexity and limited therapeutic progress. The story matters because neurodegenerative disease is becoming a proving ground for whether AI can generate value where conventional discovery and clinical approaches have struggled most.
Wearables Gain Ground as Parkinson’s Trials Search for Better, More Continuous Endpoints
Wearables are being used to track Parkinson’s symptoms in Annovis’s drug study, adding to momentum behind digital biomarkers in neurodegenerative research. The approach could make trials more sensitive to day-to-day changes that clinic visits often miss, though validation remains the key hurdle.
Breakthrough Designation for AI-Guided Memory Implant Shows Neurotech’s Regulatory Momentum
Nia Therapeutics has received FDA Breakthrough Device designation for an AI-guided brain implant intended to treat memory loss. The designation spotlights a fast-emerging intersection of neurostimulation, closed-loop algorithms, and precision neurology.
How this works
Discover
An automated pipeline searches the web for significant AI healthcare news across clinical, research, regulatory, and industry domains.
Structure
The pipeline turns source material into concise, readable stories with categories, tags, and context that make the feed easier to scan.
Publish
Stories are deduplicated, stored, and published to this site. The pipeline runs automatically to keep coverage current.